Functional abilities like strength and reaction time peak in our 20s and decline slowly but steadily. By age 50, the cumulative effect of this decline establishes a clear, visible trajectory for future healthspan, long before chronic diseases typically manifest.

Health can be managed like a technology stack, with offensive layers (nutrition, exercise) and defensive layers (medicines for lipids, blood pressure). This proactive, systematic approach uses data to extend both lifespan and healthspan by addressing key risk areas.

Beyond tackling fatal diseases to increase lifespan, a new wave of biotech innovation focuses on "health span"—the period of life lived in high quality. This includes developing treatments for conditions often dismissed as aging, such as frailty, vision loss, and hearing decline, aiming to improve wellbeing in later decades.

A major transformation has occurred in longevity science, particularly in the last eight years. The conversation has moved away from claims of radical life extension towards the more valuable goal of increasing "healthspan"—the period of healthy, functional life. This represents a significant and recent shift in scientific consensus.

The current medical model, which treats diseases one by one as they appear, is flawed for an aging population. It extends life but leads to a rise in overall frailty and disability. The only effective path forward is to directly target the underlying biological process of aging to extend healthspan.

Data from the world's longest-lived populations shows the distribution of death is compressing, not shifting to older ages. More people are reaching old age, but the curve is getting tighter, proving a biological wall for average life expectancy around 87 years. This reinforces the need to focus on healthspan.

Chronic illnesses like cancer, heart disease, and Alzheimer's typically develop over two decades before symptoms appear. This long "runway" is a massive, underutilized opportunity to identify high-risk individuals and intervene, yet medicine typically focuses on treatment only after a disease is established.

The healthcare system is fundamentally reactive, designed to intervene after a failure like a disease or injury. It overlooks the gradual decline in functional capability that precedes these events, creating a massive blind spot in preventive health for the general population.

The common aversion to living to 120 stems from assuming extra years will be spent in poor health. The goal of longevity science is to extend *healthspan*—the period of healthy, mobile life—which reframes the debate from merely adding years to adding high-quality life.